Skip to content

Effect of ResvidaTM on fat oxidation and mitochondrial biogenesis in healthy obese subjects

Effect of ResvidaTM on fat oxidation and mitochondrial biogenesis in healthy obese subjects - ResvidaTM and mitochondrial function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35600
Enrollment
18
Registered
2009-09-30
Start date
2009-11-10
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

impaired fat oxidation impaired lipid catabolism

Interventions

Subjects will receive ResvidaTM or placebo in random order. ResvidaTM is a food supplement and is regulated as a food component. ResvidaTM and placebo are supplied by DSM Nutritional Products, ltd.

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Male sex * Age 45-65 years * Body fat percentage > 25, BMI 30-35 kg/m2 * Sedentary * Stable dietary habits * Willingness to abstain from ingestion of resveratrol-containing foods * Healthy

Exclusion criteria

Exclusion criteria: * Female sex * Unstable body weight (weight gain or loss > 3 kg in the last three months) * Total body fat (%) 6.1 mmol/l HB 2 hours total per week * Impaired kidney and/ or hepatic function * First- or second-degree family member with type 2 diabetes mellitus * Any medical condition requiring treatment and/or medication use * Intake of dietary supplements except vitamins and minerals * Unwilling to restrict high-resveratrol-containing foods * Current alcohol consumption > 20 grams/day * Participation in another biomedical study within 1 month before the first screening visit * A contraindication to MRI scanning. These contra-indications include patients with the following devices: o Central nervous system aneurysm clips o Implanted neural stimulator o Implanted cardiac pacemaker of defibrillator o Cochlear implant o Insulin pump o metal containing corpora aliena in the eye or brains

Design outcomes

Primary

MeasureTime frame
The primary outcome parameter is the difference in mitochondrial number, intrinsic function and fat oxidative capacity after a 4 week treatment with ResvidaTM compared to the placebo trial.

Secondary

MeasureTime frame
Secondary endpoints are the differences in skeletal muscle and liver lipid content, and lipolysis in skeletal muscle and adipose tissue after 4 weeks ResvidaTM or placebo supplementation.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)